Is Akebia Therapeutics (Akba) a good stock to buy?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript May 9, 2024 Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08775, expectations were $-0.09. AKBA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Where can I buy Akba stock?

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. You have already added five stocks to your watchlist.

What did Akebia Therapeutics (Akba) do in the first quarter?

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the first quarter ended March 31, 2024.